Form 4: 10x Genomics CEO Serge Saxonov Sells Shares to Cover Tax Obligations

10x Genomics CEO Serge Saxonov sold 5,092 shares of Class A Common Stock on February 24, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On February 24, 2025, Serge Saxonov, the CEO of 10x Genomics, Inc., sold 5,092 shares of Class A Common Stock.
• The sale was executed at a price of $11.0656 per share.
• The transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Saxonov directly owns 879,482 shares of Class A Common Stock.
• Additionally, Saxonov indirectly owns shares through several trusts for which he serves as trustee: Andromeda Trust (27 shares), Sirius Trust (870 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (22,570 shares).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction to cover tax obligations, which is a normal part of executive compensation. It doesn't necessarily reflect a positive or negative view of the company's future.

Industry Context

This is a routine transaction for executives to cover tax obligations when stock options or restricted stock units vest. It is a common practice and doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholders, but it is unlikely to be significant given the relatively small number of shares sold compared to the total outstanding shares.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates